---
id: market_004
type: market
topic: NASH/MASH therapeutic market
disease: Nonalcoholic steatohepatitis
molecule: Resmetirom
---

Market Intelligence: NASH Market Finally Opens with First Approval

Date: September 2024

Market Catalyst: Rezdiffra (resmetirom) FDA approval March 2024 unlocked the $3-5 billion near-term NASH market opportunity.

Commercial Launch Analysis:
- Madrigal pricing: $47,400/year wholesale
- Launch trajectory: $82M Q2 2024 sales (above expectations)
- Specialty pharmacy distribution with patient support programs

Competitive Landscape:
- Akero (efruxifermin): Phase 3 ongoing, potential 2026 approval
- 89bio (pegozafermin): Strong Phase 2b data, partnered with Lilly
- Novo Nordisk: Semaglutide exploring NASH indication

Payer Dynamics:
- Prior authorization required (biopsy-confirmed NASH F2-F3)
- Limited formulary coverage initially
- Real-world adherence data critical for coverage expansion

Market Sizing:
- 6-8 million Americans with fibrotic NASH
- Diagnosis rates <5% currently
- Market growth depends on disease awareness and screening

Investment Signal: MODERATE. First-mover advantage for Madrigal but competitive pressure coming. Market conditioning required.

